Robbins Farley’s Haemonetics HAE Stock Holding History

Robbins Farley’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50	Closed	-$3K	–	148
2022 Q2	$3K	Buy	+50	New	+$2.96K	﹤0.01%	105

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Robbins Farley's HAE Position: Q3 2022 in Review

Robbins Farley sold out of Haemonetics (HAE) in Q3 2022, closing a stake of 50 shares — an estimated $3K sold.

Robbins Farley first reported a position in HAE in Q2 2022 and held it in 1 quarter. The position peaked at $3K in Q2 2022. 270 funds tracked by Wall St. Rank hold HAE as of Q3 2022.

Robbins Farley reported no remaining Haemonetics position as of Q3 2022 after selling out during the quarter.
Robbins Farley sold 50 Haemonetics shares in Q3 2022, an estimated $3K.
Robbins Farley first reported a position in Haemonetics in Q2 2022 and held it in 1 quarter.
Robbins Farley's Haemonetics position peaked at $3K in Q2 2022.
270 funds tracked by Wall St. Rank held Haemonetics as of Q3 2022.

Based on Robbins Farley's 13F filing for Q3 2022, filed 14 Nov 2022.